Pasquier Ludwig, Kirouani Medhi, Fanget Florian, Nomine Claire, Caillard Cécile, Arnault Vincent, Finel Jean-Baptiste, Christou Niki, Mathonnet Muriel, Trésallet Christophe, Hamy Antoine, de Calan Loïc, Brunaud Laurent, Menegaux Fabrice, Lifante Jean Christophe, Hardouin Jean Benoit, Drui Delphine, Mirallié Éric, Blanchard Claire
Clinique de Chirurgie Digestive et Endocrinienne (CCDE), Institut des Maladies de l'Appareil Digestif (IMAD), CHU Hôtel-Dieu, 1 place Alexis Ricordeau, 44093, Nantes cedex 1, France.
Service de chirurgie Générale, Viscérale et Endocrinienne, Hôpital Universitaire Pitié Salpêtrière, Paris, France.
Langenbecks Arch Surg. 2017 Mar;402(2):309-314. doi: 10.1007/s00423-017-1557-x. Epub 2017 Jan 22.
Aldosteronoma Resolution Score (ARS) is a predictive score for cure of hypertension after adrenalectomy for hyperaldosteronism and has been validated in American patients. The aim of the study was to validate this score in a French population.
Data concerning patients operated from 2002 to 2015 in 7 French University Hospitals were retrospectively collected. Diagnosis of Aldosterone-producing adenoma (APA) was confirmed with clinical and biochemical hyperaldosteronism and adrenal nodule on CT scan. Adrenal venous sampling was performed when CT failed to identify laterality. ARS is based on four variables: female sex, BMI ≤25 kg/m, duration of hypertension ≤6 years, number of antihypertensive medications ≤2. One point is attributed for the first three and 2 points for the last. Patients were considered as cured if they had no hypertension and no antihypertensive medications at least 6 months after surgery. Patients with bilateral adrenal hyperplasia were excluded.
This multicenter study included 310 patients with APA. ARS and follow-up were obtained in 257 patients. 46.6% of patients were cured and potassium serum level was normalized in 97.7%. In multivariate analysis, odds ratio for female sex, BMI ≤25 kg/m, duration of hypertension ≤6 years, and number of antihypertensive medications ≤2 were 1.60 (p = 0.09), 1.77 (p = 0.04), 1.28 (p = 0.4), 3.41 (p < 0.001), respectively. Cure rate were, respectively, 22.2, 41.4 and 74% for patients with a score ARS 0-1, 2-3, 4-5. The area under the curve (AUC) of ARS was 0.715.
ARS is not a predictive score efficient enough in a French population maybe due to different metabolic data and genetic conditions.
醛固酮瘤消退评分(ARS)是用于预测原发性醛固酮增多症患者肾上腺切除术后高血压治愈情况的评分系统,且已在美国患者中得到验证。本研究旨在验证该评分系统在法国人群中的有效性。
回顾性收集2002年至2015年期间在7家法国大学医院接受手术治疗患者的数据。通过临床和生化检查确诊为原发性醛固酮增多症且CT扫描发现肾上腺结节来确诊醛固酮分泌腺瘤(APA)。当CT无法确定病变侧别时,进行肾上腺静脉采血。ARS基于四个变量:女性、体重指数(BMI)≤25kg/m²、高血压病程≤6年、抗高血压药物数量≤2种。前三个变量各计1分,最后一个变量计2分。术后至少6个月无高血压且未服用抗高血压药物的患者被视为治愈。双侧肾上腺增生患者被排除。
这项多中心研究纳入了310例APA患者。257例患者获得了ARS评分及随访数据。46.6%的患者治愈,97.7%的患者血清钾水平恢复正常。多因素分析显示,女性、BMI≤25kg/m²、高血压病程≤6年、抗高血压药物数量≤2种的优势比分别为1.60(p=0.09)、1.77(p=0.04)、1.28(p=0.4)、3.41(p<0.001)。ARS评分为0 - 1分、2 - 3分、4 - 5分的患者治愈率分别为22.2%、41.4%和74%。ARS的曲线下面积(AUC)为0.715。
在法国人群中,ARS作为预测评分的有效性不足,可能是由于代谢数据和遗传条件不同所致。